MDM2

Rapamycin slows pulmonary fibrosis by reducing lung epithelial cell senescence in mice

The immunosuppressant suppresses epithelial-mesenchymal transition and promotes p53 degradation via the SFN-MDM2 pathway to curb fibrotic lung disease.